CELLPROTHERA
17.11.2021 16:45:12 CET | Business Wire | Press release
CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs, has strengthened its executive management team to foster the development of its main clinical program and extend it to new therapeutic indications.
Ibon Garitaonandia is appointed Chief Scientific Officer (CSO) . His extensive experience in drug discovery and in the development of novel stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years’ experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the first company to receive global regulatory approval to conduct a human pluripotent stem cell-based clinical trial for Parkinson’s disease.
Henk Streefkerk, MD PhD, takes the role of Chief Medical Officer (CMO) . He brings decades of leadership in clinical research to boost the strategic development of the company and advance its pipeline of novel therapeutic solutions. After graduating from the University Medical Center Utrecht, Henk worked as Clinical Pharmacologist for Organon/Schering-Plough in the Netherlands. He then joined Actelion in Switzerland before taking the positions of Translational Medicine Expert and later Senior Brand Safety Leader with Novartis in Basel. After Novartis, he worked as Medical Director and Chief Medical Officer of a biotech specialized in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO) . His solid history of helping companies and start-ups to scale up in their development journey is key for CellProthera as it enters its next stage of development. A lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and tax matters. He held leadership positions with Ernst & Young for more than 10 years, leading financial audits and due diligence transactions for a wide spectrum of industrial firms and as CFO, supporting the cash and financing management of listed companies in the energy and car industry.
“The arrival of these three talents - all experts in their field - in the executive management team is a great boost to our ambitious, multi-indications development program and position us ideally to accelerate our pathway to market.", stated Matthieu de Kalbermatten, Chairman of CellProthera. “The wealth of their international experience will be useful to shape and steer the company effectively during the next clinical and regulatory stages.”
CellProthera develops a medical innovation that enables a heart damaged by a heart attack to regenerate by injecting stem cells originated from the patient's own blood.
As such, each patient becomes his own source of medicine!
The stem cell product ProtheraCytes® is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future treatments that are often severe, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/fr/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dealroom and NATO Innovation Fund: European Defence, Security & Resilience Startups Smash Record with $8.7B Raised in 202510.2.2026 07:05:00 CET | Press release
The 55% year on year surge was fuelled by late-stage mega rounds, indicating a maturing ecosystem to address NATO’s capability needs.Munich retained its position as Europe's #1 DSR hub, with the UK attracting the most VC funding and Central and Eastern Europe showing the largest growth.AI dominated the sector, underpinning 44% of all DSR funding. An exclusive new report by Dealroom and the NATO Innovation Fund shows that European DSR (Defence, Security and Resilience) startups secured a record $8.7 billion in venture capital in 2025. The surge was fuelled by late-stage mega-rounds to support breakthrough technologies that help address critical capabilities for NATO nations – from freedom of operations & mobility, to awareness and decision making, and the security of critical technologies. Record funding surge powers DSR Startups to meet NATO nations’ most urgent security needs Funding for DSR startups increased by 55% year on year and is nearly four times higher than five years ago. It
4Moving Biotech Announces the Closing of a €12 Million Financing to Advance a First-in-Class DMOAD in Knee Osteoarthritis10.2.2026 06:52:00 CET | Press release
- Funding secured, extending the financial runway to reach a proof-of-concept inflection point - Company’s attractiveness reinforced through the onboarding of new investors 4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a €12 million financing, completed through a structured and coordinated funding process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209500141/en/ Francis Berenbaum (Left) Luc Boblet, Revital Rattenbach, Jérôme Vailland (Right) This financing was secured from a pool of private investors and family offices, who chose to reinforce their commitment by investing directly at the subsidiary level in 4MB. The round includes a combination of equity and loans, reflecting a flexible capital structure aligned with long-term value creation. Thi
SBTS and ZIM Connections Bring Travel eSIM to Global Travelers10.2.2026 05:00:00 CET | Press release
New service leverages SoftBank Corp.’s wireless network in Japan SBTS, the joint venture between BTS and SoftBank Corp., and ZIM Connections today announced a strategic partnership to launch a travel eSIM solution, initially focused on inbound and outbound travel into and from Japan. The service is now live and commercially available here, marking the first step in a broader global rollout of multiple travel eSIM offerings. The initial launch is a digital travel eSIM platform developed by ZIM Connections and commercialized by SoftBank Corp. (“SoftBank”), a Japan-based telecommunications and IT operator. It enables travelers to easily search for, purchase, and activate unlimited global eSIM plans through a seamless digital experience. The first phase focuses on travelers visiting Japan as well as Japan-based travelers going abroad, leveraging SoftBank’s network for connectivity in the region. This launch represents a fully commercial market introduction, delivering immediate value to tr
FPT Achieves HITRUST r2 v11.5.1 Certification, Demonstrating the Highest Level of Information Protection Assurance10.2.2026 03:00:00 CET | Press release
FPT, a leading global IT company, announced its in-scope platforms and facilities of FPT Data Center have earned certified status from HITRUST for cybersecurity and information protection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209729954/en/ The scope of the HITRUST r2 v11.5.1 certification includes FPT’s Application Services System, Database System, and Deployment System, all hosted and managed within the FPT Data Center in Hanoi, Vietnam, as well as the data center facility itself. The HITRUST Certification demonstrates that FPT has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls are in place to protect sensitive data and manage risk effectively. The certification also includes the HITRUST AI Security Certification, which validates that the organization’s AI systems are safeguarded against AI-specific threats such as data poisoning, model inversion, an
SheltonAI Announces Global Expansion, Senior Leadership Appointments, and Accelerated Growth9.2.2026 23:04:00 CET | Press release
SheltonAI, the institutional AI platform for valuation, announced senior executive appointments, major global expansion, and strong growth momentum entering 2026. SheltonAI announced several senior leadership appointments, including: Stephen Can, CSO, previously Executive Chairman & Founder of Blackstone Strategic Partners Peter Song, COO, previously COO of Blackstone Strategic Partners Chris Cooper, CFO, previously Global CFO at Sequoia, SoftBank, & Clearlake Capital Paige Shiring, has been promoted to Director, previously with Thoma Bravo 2026 NY Analyst Class & 10+ Hires in January SheltonAI also plans to open several regional HQs in 2026, including: New YorkSydneyGCC Region, with office lead to be announced later in Feb 2026 The company reported significant momentum entering the year, including 10+ new hires in January and over $1 trillion in incremental assets supported by the platform during the month, driven by new client deployments and expanded mandates. SheltonAI’s platform p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom